BioSpace News Archive

Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, acknowledged the sudden passing of Tadataka Yamada, M.D., co-founder and Chairman of the Board of Icosavax, who died unexpectedly on August 4, 2021.

BioVie Inc., a clinical-stage company developing innovative drug candidates for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, announced that the Company has enrolled the first patient into the NM101 Phase III clinical study testing NE3107 for the treatment of Alzheimer’s Disease.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the second quarter ending June 30, 2021 and provided an update on clinical and corporate activities.

Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, inflammation, and other indications announced the successful completion of a $29 million Series B financing.

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for avexitide for the treatment of congenital hyperinsulism.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, reported financial results for the second quarter ended June 30, 2021 and provided recent business highlights.

Landos Biopharma, Inc., a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos and additional management team members will participate in the following investor events in August.

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2021, and provided a corporate update.

Baudax Bio, Inc., a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, reported financial results for the three and six months ended June 30, 2021.